1. Introduction
2. Patients and Methods
2.1. Patients’ Selection and Data Collection
2.2. Objectives
2.3. Statistical Methods
3. Results
3.1. Induction Therapy
3.2. Surgery
3.3. Post-Operative RT
3.4. Post-Operative CT
3.5. Follow-Up and Efficacy Outcomes
4. Comment
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tossavainen, A. Global use of asbestos and the incidence of mesothelioma. Int. J. Occup. Environ. Health 2004, 10, 22–25. [Google Scholar] [CrossRef] [PubMed]
- Popat, S.; Baas, P.; Faivre-Finn, C.; Girard, N.; Nicholson, A.G.; Nowak, A.K.; Opitz, I.; Scherpereel, A.; Reck, M.; on behalf of the ESMO Guidelines Committee. Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2021. in press. [Google Scholar] [CrossRef] [PubMed]
- Metintas, M.; Ucgun, I.; Elbek, O.; Erginel, S.; Metintas, S.; Kolsuz, M.; Harmanci, E.; Alatas, F.; Hillerdal, G.; Ozkan, R.; et al. Computed tomography features in malignant pleural mesothelioma and other commonly seen pleural diseases. Eur. J. Radiol. 2002, 41, 1–9. [Google Scholar] [CrossRef]
- Kim, R.Y.; Sterman, D.H.; Haas, A.R. Malignant Mesothelioma: Has Anything Changed? Semin. Respir. Crit. Care Med. 2019, 40, 347–360. [Google Scholar] [CrossRef] [PubMed]
- Zauderer, M.G.; Krug, L.M. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr. Treat. Options Oncol. 2011, 12, 163–172. [Google Scholar] [CrossRef][Green Version]
- Buduhan, G.; Menon, S.; Aye, R.; Louie, B.; Mehta, V.; Vallières, E. Trimodality therapy for malignant pleural mesothelioma. Ann. Thorac. Surg. 2009, 88, 870–875. [Google Scholar] [CrossRef]
- Viscardi, G.; Di Liello, R.; Morgillo, F. How I treat malignant pleural mesothelioma. ESMO Open 2020, 4, e000669. [Google Scholar] [CrossRef][Green Version]
- Verma, V.; Ahern, C.A.; Berlind, C.G.; Lindsay, W.D.; Sharma, S.; Shabason, J.; Culligan, M.J.; Grover, S.; Friedberg, J.S.; Simone, C.B. National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma. J. Thorac. Oncol. 2017, 12, 1704–1714. [Google Scholar] [CrossRef][Green Version]
- Bovolato, P.; Casadio, C.; Billè, A.; Ardissone, F.; Santambrogio, L.; Ratto, G.B.; Garofalo, G.; Bedini, A.V.; Garassino, M.; Porcu, L.; et al. Does Surgery Improve Survival of Patients with Malignant Pleural Mesothelioma?: A Multicenter Retrospective Analysis of 1365 Consecutive Patients. J. Thorac. Oncol. 2014, 9, 390–396. [Google Scholar] [CrossRef][Green Version]
- Sugarbaker, D.J.; Jaklitsch, M.T.; Bueno, R.; Richards, W.; Lukanich, J.; Mentzer, S.J.; Colson, Y.; Linden, P.; Chang, M.; Capalbo, L.; et al. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J. Thorac. Cardiovasc. Surg. 2004, 128, 138–146. [Google Scholar] [CrossRef][Green Version]
- Bertoglio, P.; Ambrogi, M.C.; Chella, A.; Aprile, V.; Dini, P.; Korasidis, S.; Fanucchi, O.; Mussi, A. Is less also better? A single-institution experience on treatment of early stage Malignant Pleural Mesothelioma. Eur. J. Surg. Oncol. 2017, 43, 1365–1371. [Google Scholar] [CrossRef] [PubMed]
- Santini, M.; Vicidomini, G. Instrumental diagnosis of mesothelioma: The thoracoscopy. In Mesothelioma from the Bench Side to Clinic; Baldi, A., Ed.; Nova Science Publishers: Hauppauge, NY, USA, 2008; pp. 389–403. ISBN 9781600217890. [Google Scholar]
- Hasegawa, S.; Kondo, N.; Matsumoto, S.; Takuwa, T.; Hashimoto, M.; Kuroda, A.; Nakamichi, T.; Kamikonya, N.; Tsujimura, T.; Nakano, T. Surgical Risk and Survival Associated with Less Invasive Surgery for Malignant Pleural Mesothelioma. Semin. Thorac. Cardiovasc. Surg. 2019, 31, 301–309. [Google Scholar] [CrossRef] [PubMed]
- Lang-Lazdunski, L.; Bille, A.; Papa, S.; Marshall, S.; Lal, R.; Galeone, C.; Landau, D.; Steele, J.; Spicer, J. Pleurectomy/decortication, hyperthermic pleural lavage with povidone-iodine, prophylactic radiotherapy, and systemic chemotherapy in patients with malignant pleural mesothelioma: A 10-year experience. J. Thorac. Cardiovasc. Surg. 2015, 149, 556–558. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Pass, H.I.; Kranda, K.; Temeck, B.K.; Feuerstein, I.; Steinberg, S.M. Surgically debulked malignant pleural mesothelioma: Results and prognostic factors. Ann. Surg. Oncol. 1997, 4, 215–222. [Google Scholar] [CrossRef] [PubMed]
- Sugarbaker, D.J.; Flores, R.M.; Jaklitsch, M.T.; Richards, W.G.; Strauss, G.M.; Corson, J.M.; DeCamp, M.M.J.; Swanson, S.J.; Bueno, R.; Lukanich, J.M.; et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: Results in 183 patients. J. Thorac. Cardiovasc. Surg. 1999, 117, 54–55. [Google Scholar] [CrossRef][Green Version]
- Treasure, T.; Lang-Lazdunski, L.; Waller, D.; Bliss, J.M.; Tan, C.; Entwisle, J.; Snee, M.; O’Brien, M.; Thomas, G.; Senan, S.; et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: Clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011, 12, 763–772. [Google Scholar] [CrossRef]
- Bölükbas, S.; Manegold, C.; Eberlein, M.; Bergmann, T.; Fisseler-Eckhoff, A.; Schirren, J. Survival after trimodality therapy for malignant pleural mesothelioma: Radical Pleurectomy, chemotherapy with Cisplatin/Pemetrexed and radiotherapy. Lung Cancer 2011, 71, 75–81. [Google Scholar] [CrossRef]
- Lim, E.; Darlison, L.; Edwards, J.; Elliott, D.; Fennell, D.A.; Popat, S.; Rintoul, R.C.; Waller, D.; Ali, C.; Bille, A.; et al. Mesothelioma and Radical Surgery 2 (MARS 2): Protocol for a multicentre randomised trial comparing (extended) pleurectomy decortication versus no (extended) pleurectomy decortication for patients with malignant pleural mesothelioma. BMJ Open 2020, 10, e038892. [Google Scholar] [CrossRef]
- Rosskamp, M.; Macq, G.; Nackaerts, K.; Praet, M.; Van Eycken, L.; Van Meerbeeck, J.P.; De Schutter, H. Real-life treatment practice for malignant pleural mesothelioma in Belgium. Lung Cancer 2018, 125, 258–264. [Google Scholar] [CrossRef]
- Saddoughi, S.A.; Abdelsattar, Z.M.; Blackmon, S.H. National Trends in the Epidemiology of Malignant Pleural Mesothelioma: A National Cancer Data Base Study. Ann. Thorac. Surg. 2018, 105, 432–437. [Google Scholar] [CrossRef] [PubMed][Green Version]
- De Perrot, M.; Wu, L.; Wu, M.; Cho, B.C.J. Radiotherapy for the treatment of malignant pleural mesothelioma. Lancet Oncol. 2017, 18, e532–e542. [Google Scholar] [CrossRef]
- Dumane, V.; Yorke, E.; Rimner, A.; RosenzweigG, K. SU-E-T-595: Comparison of Volumetric Modulated Arc Therapy (VMAT) and Static Intensity Modulated Radiotherapy (IMRT) for Malignant Pleural Mesothelioma in Patients with Intact Lungs/Post Pleurectomy. Med. Phys. 2012, 39, 3842. [Google Scholar] [CrossRef]
- Raskin, J.; Surmont, V.; Cornelissen, R.; Baas, P.; van Schil, P.E.Y.; van Meerbeeck, J.P. A randomized phase II study of pleurectomy/decortication preceded or followed by (neo-)adjuvant chemotherapy in patients with early stage malignant pleural mesothelioma (EORTC 1205). Transl. Lung Cancer Res. 2018, 7, 593–598. [Google Scholar] [CrossRef]
- Oehl, K.; Vrugt, B.; Wagner, U.; Kirschner, M.B.; Meerang, M.; Weder, W.; Felley-Bosco, E.; Wollscheid, B.; Bankov, K.; Demes, M.C.; et al. Alterations in BAP1 Are Associated with Cisplatin Resistance through Inhibition of Apoptosis in Malignant Pleural Mesothelioma. Clin. Cancer Res. 2021, 27, 2277–2291. [Google Scholar] [CrossRef]
- Hassan, R.; Morrow, B.; Thomas, A.; Walsh, T.; Lee, M.K.; Gulsuner, S.; Gadiraju, M.; Panou, V.; Gao, S.; Mian, I.; et al. Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proc. Natl. Acad. Sci. USA 2019, 116, 9008–9013. [Google Scholar] [CrossRef][Green Version]
- Fennell, D.A.; King, A.; Mohammed, S.; Branson, A.; Brookes, C.; Darlison, L.; Dawson, A.G.; Gaba, A.; Hutka, M.; Morgan, B.; et al. Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): An open-label, single-arm, phase 2a clinical trial. Lancet. Respir. Med. 2021, 9, 593–600. [Google Scholar] [CrossRef]
- Gomez, D.R.; Rimner, A.; Simone, C.B.; Cho, B.C.J.; de Perrot, M.; Adjei, A.A.; Bueno, R.; Gill, R.R.; Harpole, D.H.; Hesdorffer, M.; et al. The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Re. J. Thorac. Oncol. 2019, 14, 1172–1183. [Google Scholar] [CrossRef] [PubMed][Green Version]
- Rosenzweig, K.E. Radiation Therapy for Malignant Pleural Mesothelioma. Thorac. Surg. Clin. 2020, 30, 473–480. [Google Scholar] [CrossRef] [PubMed]
- Van Gerwen, M.; Wolf, A.; Liu, B.; Flores, R.; Taioli, E. Short-term outcomes of pleurectomy decortication and extrapleural pneumonectomy in mesothelioma. J. Surg. Oncol. 2018, 118, 1178–1187. [Google Scholar] [CrossRef] [PubMed]
- Euhus, C.J.; Ripley, R.T. The Staging of Malignant Pleural Mesothelioma. Thorac. Surg. Clin. 2020, 30, 425–433. [Google Scholar] [CrossRef]
- Weder, W.; Stahel, R.A.; Bernhard, J.; Bodis, S.; Vogt, P.; Ballabeni, P.; Lardinois, D.; Betticher, D.; Schmid, R.; Stupp, R.; et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann. Oncol. 2007, 18, 1196–1202. [Google Scholar] [CrossRef] [PubMed]
- Cao, C.; Tian, D.H.; Pataky, K.A.; Yan, T.D. Systematic review of pleurectomy in the treatment of malignant pleural mesothelioma. Lung Cancer 2013, 81, 319–327. [Google Scholar] [CrossRef] [PubMed]



Age, Median (Range) | 66 (58–73) |
Age category, n (%) | |
<70 | 15 (88.2) |
≥70 | 2 (11.8) |
Sex, n (%) | |
Male | 12 (70.6) |
Female | 5 (29.4) |
ECOG PS, n (%) | |
0 | 5 (29.4) |
1 | 10 (58.8) |
2 | 2 (11.8) |
Smoking status, n (%) | |
Current/former | 15 (88.2) |
Never | 2 (11.8) |
Asbestos exposure, n (%) | |
Yes | 12 (70.6) |
No | 5 (29.4) |
Clinical stage, n (%) | |
I | 14 (82.4) |
II | 3 (17.6) |
Histology, n (%) | |
Epithelioid | 15 (88.2) |
Sarcomatoid | 0 (0) |
Biphasic | 2 (11.8) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).